# Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia

> **NCT01543477** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 4501 (actual)

## Conditions studied

- Renal Anemia
- Pregnancy
- Lactation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01543477
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-07
- **Primary completion:** 2020-04-29
- **Final completion:** 2020-04-29
- **Target enrollment:** 4501 (ACTUAL)
- **Last updated:** 2020-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01543477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01543477, "Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01543477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*